{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:40:58Z","timestamp":1794487258393,"version":"4.9.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1093\/jnci\/djt378","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T23:06:38Z","timestamp":1391468798000},"source":"Crossref","is-referenced-by-count":197,"title":["Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase\u2013Positive Lymphoma Patients"],"prefix":"10.1093","volume":"106","author":[{"given":"Carlo","family":"Gambacorti Passerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Stasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Redaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ceccon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mologni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Messa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Mussolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dries","family":"Deeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Ordemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Grube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Chiriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Antolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,31]]},"reference":[{"issue":"1","key":"key\n\t\t\t\t20170520221516_CIT0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"key\n\t\t\t\t20170520221516_CIT0002","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood.V87.1.284.284","article-title":"High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin\u2019s disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining","volume":"87","author":"Lamant","year":"1996","journal-title":"Blood"},{"issue":"2","key":"key\n\t\t\t\t20170520221516_CIT0003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.1990.tb02560.x","article-title":"CD30-positive large cell lymphomas (\u2018Ki-1 lymphoma\u2019) are associated with a chromosomal translocation involving 5q35","volume":"74","author":"Mason","year":"1990","journal-title":"Br J Haematol"},{"issue":"5151","key":"key\n\t\t\t\t20170520221516_CIT0004","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"key\n\t\t\t\t20170520221516_CIT0005","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","edition":"4th"},{"issue":"2","key":"key\n\t\t\t\t20170520221516_CIT0006","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.critrevonc.2012.02.005","article-title":"Anaplastic large cell lymphoma, ALK-positive","volume":"83","author":"Ferreri","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"key\n\t\t\t\t20170520221516_CIT0007","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"issue":"12","key":"key\n\t\t\t\t20170520221516_CIT0008","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"16","key":"key\n\t\t\t\t20170520221516_CIT0009","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","journal-title":"J Clin Oncol"},{"issue":"18","key":"key\n\t\t\t\t20170520221516_CIT0010","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"key\n\t\t\t\t20170520221516_CIT0011","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in anaplastic large-cell lymphoma","volume":"364","author":"Gambacorti-Passerini","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"key\n\t\t\t\t20170520221516_CIT0012","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/dc.10315","article-title":"Detection of a subset of CD30+ anaplastic large cell lymphoma by interphase fluorescence in situ hybridization","volume":"29","author":"Shin","year":"2003","journal-title":"Diagn Cytopathol"},{"issue":"3","key":"key\n\t\t\t\t20170520221516_CIT0013","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20170520221516_CIT0014","volume-title":"Analyzing Survival Data from Clinical Trials and Observational Studies","author":"Marubini","year":"1995"},{"issue":"2","key":"key\n\t\t\t\t20170520221516_CIT0015","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/leu.2012.205","article-title":"Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis","volume":"27","author":"Mussolin","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"key\n\t\t\t\t20170520221516_CIT0016","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"key\n\t\t\t\t20170520221516_CIT0017","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1541-7786.MCR-12-0569","article-title":"Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors","volume":"11","author":"Ceccon","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"3","key":"key\n\t\t\t\t20170520221516_CIT0018","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18","key":"key\n\t\t\t\t20170520221516_CIT0019","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"key\n\t\t\t\t20170520221516_CIT0020","first-page":"2745","article-title":"Long-term remissions observed in an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"120","author":"Pro","year":"2012","journal-title":"ASH Ann Mtng Abst"},{"issue":"6","key":"key\n\t\t\t\t20170520221516_CIT0021","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study","volume":"14","author":"Mosse","year":"2012","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170520221516_CIT0022","first-page":"4342","article-title":"Safety and clinical activity of crizotinib in patients with ALK-rearranged hematologic malignancies","volume-title":"ASH Ann Mtng Abst","author":"Carlo Gambacorti-Passerini","year":"2013"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/106\/2\/djt378\/17313236\/djt378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T02:40:06Z","timestamp":1688956806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djt378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,31]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,31]]},"published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djt378","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718264959.793490587","asserted-by":"object"}]},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,31]]}}}